Navigation Links
Ubiquitin Fraction I from ABR-Affinity BioReagents

ProductsUbiquitin Fraction I from ABR-Affinity BioReagents
Company ABR-Affinity BioReagents
Item Ubiquitin Fraction I
Price $355.00
Description Proteolytic degradation is critical to the maintenance of appropriate levels of short-lived and regulatory proteins as important and diverse as those involved in cellular metabolism, heat shock and stress response, antigen presentation, modulation of cell surface receptors and ion channels, cell cycle regulation, transcription, and signalling factors. The ubiquitin-proteasome pathway deconstructs most proteins in the eukaryotic cell cytosol and nucleus. Others are degraded via the vacuolar pathway which includes endosomes, lysosomes, and the endoplasmic reticulum.

The 26S proteasome is an ATP-dependent, multisubunit (~31), barrel-shaped molecular machine with an apparent molecular weight of ~2.5 MDa. It consists of a 20S proteolytic core complex which is crowned at one or both ends by 19S regulatory subunit complexes. The 19S regulatory subunits recognize ubiquitinated proteins and play an essential role in unfolding and translocating targets into the lumen of the 20S subunit. An enzymatic cascade is responsible for the attachment of multiple ubiquitin molecules to lysine residues of proteins targeted for degradation. Several genetic diseases are associated with defects in the ubiquitin-proteasome pathway. Some examples of affected proteins include those linked to cystic fibrosis, Angelmans syndrome, and Liddle syndrome.

EP-500 is the protein fraction of HeLa cell extract that does not bind to anion exchange resin. EP-500 contains ubiquitin, ubiquitin conjugating enzymes (E2s), and ubiquitin ligases (E3s). EP-500 is ideal for demonstrating if FI enzymes are critical for degradation of in vitro substrates as well as in vitro conjugation activity.

Info ABR-Affinity BioReagentsABR-Affinity BioReagents
ABR-Affinity BioReagents Inc.
4620 Technology Drive, Suite 600
Golden, CO 80403
USA

Customer Service: +1.800.527.4535
Fax Number: +1.303.278.2424
Web Site: http://www.bioreagents.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Ubiquitin/Proteasome Fraction II Extract from GeneTex
2. Ubiquitin Fraction I Extract from GeneTex
3. Mouse Anti-Ubiquitin, Multi Monoclonal Antibody, Unconjugated, Clone FK2 from Assay Designs/Stressgen Bioreagents
4. Ubiquitin Related I Sampler Kit from BD Biosciences Pharmingen
5. Rabbit Anti-Human Ubiquitin-conjugating enzyme E2N Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
6. ProteomeLab PF 2D Protein Fractionation System from Beckman Coulter
7. UBC Fractions Extract from GeneTex
8. 26S Proteasome Fraction Extract from GeneTex
9. 26S Proteasome Fraction Extract from GeneTex
10. FractionPREP Cell Fractionation Kit from BioVision
11. cDNA Size Fractionation Columns from Invitrogen
...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... 178-227 of human YBX2. (Note: ... proprietary). ...
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
... General description: Aminopropylsilane is ... used slide chemistry for ... Coated Slides for Microarrays ... glass substrate for printing ...
Biology Products:
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... chloride ions are critical to hearing in mammals, which builds ... off boats might disrupt the balance of these ions in ... show that chloride ions are crucial for our exquisite sense ... Surgery and Neurobiology and first author of the study in ...
... and harvest gardens of fungus have a secret ... antibiotic-producing bacteria that the insects harbor on their ... an international team led by University of Wisconsin-Madison ... nature of this mutualistic relationship. The researchers ...
... beaches hit Rhode Island's Narragansett Bay during the summer ... which literally suffocates sea life. While some evidence of ... surface, Brown University ecologists went underwater and discovered a ... mussel reefs located in the central bay, researchers found ...
Cached Biology News:Study reveals classic symbiotic relationship between ants, bacteria 2Study reveals classic symbiotic relationship between ants, bacteria 3'Dead zone' summer killed billions of ocean state mussels 2
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5